A
Alan R. Zinsmeister
Researcher at Mayo Clinic
Publications - 542
Citations - 56210
Alan R. Zinsmeister is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Population & Gastric emptying. The author has an hindex of 118, co-authored 542 publications receiving 52909 citations. Previous affiliations of Alan R. Zinsmeister include University of Rochester & University of Southern California.
Papers
More filters
Journal ArticleDOI
Prevalence and clinical spectrum of gastroesophageal reflux : a population-based study in Olmsted County, Minnesota
TL;DR: Symptoms of reflux are common among white men and women who are 25-74 years of age and heartburn and acid regurgitation are significantly associated with chest pain, dysphagia, dyspepsia, and globus sensation.
Journal ArticleDOI
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
William A. Faubion,Edward V. Loftus,William S. Harmsen,Alan R. Zinsmeister,William J. Sandborn +4 more
TL;DR: At 1 year, 32% of patients with Crohn's disease and 48% with ulcerative colitis are corticosteroid free without operation.
Journal ArticleDOI
Risk factors for opportunistic infections in patients with inflammatory bowel disease.
Murat Törüner,Edward V. Loftus,W. Scott Harmsen,Alan R. Zinsmeister,Robert Orenstein,William J. Sandborn,Jean-Frederic Colombel,Laurence J. Egan,Laurence J. Egan +8 more
TL;DR: Immunosuppressive medications, especially when used in combination, and older age are associated with increased risk of opportunistic infections in inflammatory bowel disease patients.
Journal ArticleDOI
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.
David A. Schwartz,Edward V. Loftus,William J. Tremaine,Remo Panaccione,W. Scott Harmsen,Alan R. Zinsmeister,William J. Sandborn +6 more
TL;DR: F Fistulas in Crohn's disease were common in the community, and in contrast to referral-based studies, only 34% of patients developed recurrent fistulas.
Journal ArticleDOI
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
William J. Sandborn,Stephen B. Hanauer,Seymour Katz,Michael Safdi,Douglas G. Wolf,Richard D. Baerg,William J. Tremaine,Therese Johnson,Nancy N. Diehl,Alan R. Zinsmeister +9 more
TL;DR: Subcutaneous etanercept at a dose of 25 mg twice weekly is safe, but not effective, for the treatment of patients with moderate to severe Crohn's disease.